Findings for the Combination of Anti-TIM-3 and Anti-PD-1 in Melanoma and Lung Cancer
December 27th 2018Diwakar Davar, MBBS, MSc, discusses how data from the phase I trial of TSR-022, an anti-TIM-3 monoclonal antibody, and TSR-042, an anti-PD-1 agent, impact the treatment of patients with both melanoma and lung cancer.